{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:20:51Z","timestamp":1787775651699,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Metformin as an oral antidiabetic drug (OAD) is not recommended in renal failure due to the presumed risk of lactic acidosis though it has advantages in cardiovascular protection with a low risk of hypoglycemia. Few studies have measured lactic acid blood levels in patients with diabetic kidney disease on metformin and demonstrated lactic acidosis. The aim of our study is to see if patients with diabetic kidney disease are at risk of elevated lactate blood levels and lactic acidosis. Lactate levels and blood pH were estimated in patients with type 2 diabetes mellitus receiving metformin in different stages of chronic kidney disease (CKD) and were compared with a similar group not receiving metformin. Patients with diabetic kidney disease, with estimated glomerular filtration rate &lt;60 mL\/min who were previously receiving metformin started in centers elsewhere and referred here were studied and compared with a similar group taking other OADs or insulin. Independent sample t-test or ANOVA were used to compare quantitative variables between groups. Pearson correlation was used to analyze association between quantitative variables and linear regression analysis and was employed to note the relationship between quantitative variables. Of 57 patients who received a mean dose of 1.134 grams of metformin, 33 (55.9%) were in stage 3, 16 (28.1%) in stage 4, and 8 (14%) in stage 5 CKD. Mean serum pH (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.572), bicarbonate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.978), and plasma lactate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.449) levels in those taking and not taking metformin were comparable. There was no difference in the plasma lactate levels in different stages of CKD in the metformin group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.498) although there was significant correlation with metformin dose (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05). Blood lactate levels were not elevated in patients with diabetic kidney disease at a daily dose of metformin &lt;1 g.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/1319-2442.220870","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T23:35:26Z","timestamp":1513640126000},"page":"1356-1361","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Lactate Levels and Risk of Lactic Acidosis with Metformin in Diabetic Kidney Disease Patients"],"prefix":"10.4103","volume":"28","author":[{"given":"P. K.","family":"Bipi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gomathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noble","family":"Gracious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Mohandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-14-20260302","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/j.1552-4604.1995.tb04033.x","article-title":"Kidney function and age are both predictors of pharmacokinetics of metformin","volume":"35","author":"Sambol","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"R3-14-20260302","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"R4-14-20260302","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"R7-14-20260302","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2337\/diab.24.1.28","article-title":"Insulin therapy in phenformin-associated lactic acidosis; a case report, biochemical considerations and review of the literature","volume":"24","author":"Dembo","year":"1975","journal-title":"Diabetes"},{"key":"R8-14-20260302","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"R9-14-20260302","first-page":"205","article-title":"Effect of phenformin on the metabolism of glucose, pyruvate and acetate in guinea-pig heart","volume":"6","author":"R\u00f6sen","year":"1980","journal-title":"Diabete Metab"},{"key":"R10-14-20260302","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/diab.46.9.1406","article-title":"Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver","volume":"46","author":"Radziuk","year":"1997","journal-title":"Diabetes"},{"key":"R11-14-20260302","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2796.2003.01271.x","article-title":"Metformin and lactic acidosis: Cause or coincidence? A review of case reports","volume":"255","author":"Stades","year":"2004","journal-title":"J Intern Med"},{"key":"R12-14-20260302","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"4","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-14-20260302","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: A nested casecontrol analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"key":"R14-14-20260302","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/bj2190073","article-title":"The influence of renal function on lactate and glucose metabolism","volume":"219","author":"Bartlett","year":"1984","journal-title":"Biochem J"},{"key":"R15-14-20260302","doi-asserted-by":"crossref","first-page":"e001076","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: A cohort study from the Swedish national diabetes register","volume":"2","author":"Ekstr\u00f6m","year":"2012","journal-title":"BMJ Open"},{"key":"R16-14-20260302","first-page":"121","article-title":"The contribution of the kidney to the removal of a lactic acid load under normal and acidotic conditions in the conscious rat","volume":"48","author":"Yudkin","year":"1975","journal-title":"Clin Sci Mol Med"},{"key":"R17-14-20260302","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1742-1241.2007.01487.x","article-title":"Lactate levels in Asian patients with type 2 diabetes mellitus on metformin and its association with dose of metformin and renal function","volume":"61","author":"Lim","year":"2007","journal-title":"Int J Clin Pract"},{"key":"R18-14-20260302","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ndtplus\/sfr134","article-title":"Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease","volume":"5","author":"Briet","year":"2012","journal-title":"Clin Kidney J"},{"key":"R19-14-20260302","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: Current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"R20-14-20260302","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3803\/EnM.2015.30.1.78","article-title":"Metformin-associated lactic acidosis: Predisposing factors and outcome","volume":"30","author":"Kim","year":"2015","journal-title":"Endocrinol Metab (Seoul"},{"key":"R21-14-20260302","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1463-1326.2000.00053.x","article-title":"Metformin and lactic acidosis in diabetic humans","volume":"2","author":"Lalau","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"R22-14-20260302","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/dme.12515","article-title":"A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure","volume":"31","author":"Adam","year":"2014","journal-title":"Diabet Med"},{"key":"R23-14-20260302","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00002018-199920040-00006","article-title":"Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations","volume":"20","author":"Lalau","year":"1999","journal-title":"Drug Saf"},{"key":"R24-14-20260302","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10863-006-9003-8","article-title":"The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin","volume":"38","author":"Batandier","year":"2006","journal-title":"J Bioenerg Biomembr"},{"key":"R25-14-20260302","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/diabetes.54.7.2179","article-title":"Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process","volume":"54","author":"Detaille","year":"2005","journal-title":"Diabetes"},{"key":"R26-14-20260302","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"R27-14-20260302","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ki.2014.19","article-title":"Metformin and other antidiabetic agents in renal failure patients","volume":"87","author":"Lalau","year":"2015","journal-title":"Kidney Int"},{"key":"R28-14-20260302","doi-asserted-by":"crossref","first-page":"c380","DOI":"10.1159\/000323739","article-title":"Metformin: The safest hypoglycaemic agent in chronic kidney disease","volume":"118","author":"Nye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"R29-14-20260302","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.ajkd.2015.04.001","article-title":"Metformin use in type 2 diabetes mellitus with CKD: Is it time to liberalize dosing recommendations","volume":"66","author":"Stanton","year":"2015","journal-title":"Am J Kidney Dis"}],"container-title":["Saudi Journal of Kidney Diseases and Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00936703-201728060-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:37:38Z","timestamp":1787773058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00936703-201728060-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/1319-2442.220870","relation":{},"ISSN":["1319-2442"],"issn-type":[{"value":"1319-2442","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}